Dermatomycoses is a fungal infection of the skin commonly caused by yeast, dermatophytes or other groups of fungi (e.g. epidermophyton, microsporum and genera trichophyton). These organisms break down the keratin tissues of hair, epidermis, nails and are mainly characterized by colonization of the keratinized layers on the surface of skin. Dermatomycoses commonly refers as tinea or ring-worm infections due to its characteristic ringed lesions. It comprises various types of ringworm infections namely athelete’s foot, microsporosis, jock itch and trichophytosis. The possible route of entry for these organisms (i.e. dermatophytes) into the host body is by scars, burns and injured skin.

View Report-

https://www.transparencymarketresearch.com/dermatomycoses-market.html

These organisms invade into the layer of skin and spread infection. It may cause inflammation of skin, hair folicles and nails due to infection. Dermatomycoses leads to scaly, dry red patches on skin that slowly spreads on the surface of the skin. Diabetes, weak immune system (e.g. AIDS), overweight are some of the conditions that increases the risk of dermatomycoses infection. Dermatomycoses is currently treated with commercially available antifungal creams (such as benzoic acid, ketoconazole and allylamine) and tablets. In addition, following proper personal hygiene and use of protective clothing are also advisable for the control of these types of infections.

The escalating demand for dermatomycoses drugs has been attributed to the rise in cases of fungal infections globally. According to World Health Organization, approximately 20% of the world population suffers from mycosis infections and the percentage is even higher in tropical and subtropical areas. In addition, advancements in science and technologies that enables to develop novel and cost effective anti-dermatophytic drugs will further drive the growth of this market. Additionally, technological advancements have increased the penetration ability of these drugs. This factor permits effective and quick treatment options for fungal infections that attracts more number of customers to use these drugs and hence stimulates the market growth. Furthermore, diabetic patients are more susceptible to dermatomycoses infections. Increasing number of diabetic patients will indirectly augment the growth of this market.

Request Brochure-

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2240

For example, According to National Diabetes Information Clearinghouse (NDIC), in 2010 approximately 10.9 million U.S. people were diagnosed with diabetes and the number is increasing every year. However, less specific actions of anti-fungal drugs for the treatment of dermatomycoses infections restrains the growth of global dermatomycoses market. In addition, high rate of side effects like constipation, hepatitis, inhibition of the synthesis of steroid hormones and pruritis also restricts the growth of this market.

Geographically, North America dominates the global dermatomycoses market. The growth is mainly attributed to increase in cases of skin infections and rise in treatment seeking population in North America. Europe is considered as the second largest region for dermatomycoses market. Increasing uptake of anti-dermatophytic drugs coupled with advancement in technologies drives the growth of this market in Europe. The market of dermatomycoses in Asia-Pacific holds a strong growth as hot climate and humid weather of this region is a favorable condition for the development of these infectious organisms. Thus, favorable conditions may lead to increase in cases of fungal infections that may enhance the treatment seeking population and hence drives the growth of this market.

Request for TOC containing Tables and Figures: 

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=2240

Various key players contributing to this market comprises AstraZeneca PLC, Vectura Group plc, Helix BioMedix, Inc., Aegera Therapeutics, Inc., Amplyx Pharmaceuticals, Inc., Globeimmune, Inc., Eli Lilly and Company, Aparna Biosciences Corporation and others